Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pediatr Adolesc Gynecol ; 37(3): 375-377, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38113972

RESUMEN

Nonsexual acute genital ulcerations (NAGUs), also known as Lipschütz ulcers, are vulvar ulcers occurring predominantly in adolescent females. Although the pathogenesis is unknown, NAGUs are commonly associated with systemic infections. Here, we present a female child with NAGU along with disseminated Lyme disease. We believe this is the first reported pediatric case of this phenomenon.


Asunto(s)
Enfermedad de Lyme , Úlcera , Enfermedades de la Vulva , Humanos , Femenino , Úlcera/etiología , Enfermedad de Lyme/complicaciones , Enfermedad de Lyme/diagnóstico , Enfermedad de Lyme/tratamiento farmacológico , Enfermedades de la Vulva/etiología , Enfermedades de la Vulva/microbiología , Enfermedades de la Vulva/diagnóstico , Enfermedades de la Vulva/tratamiento farmacológico , Niño , Adolescente , Antibacterianos/uso terapéutico , Enfermedad Aguda
2.
Curr Opin Obstet Gynecol ; 30(1): 1-6, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29251676

RESUMEN

PURPOSE OF REVIEW: The current article reviews the advances and challenges in the fight with cancer and the hope for cure, with a focus on clinical trials, at the one time with the best outcomes; first-line therapy. RECENT FINDINGS: To date there have been four great stories that bridge inception to development of new drugs in ovarian cancer: Serendipitous insight into the role of platinum, discovery of taxanes, understanding the microenvironment and angiogenesis, and following the science in the development of Poly (ADP-Ribose) Polymerase (PARP) inhibitors. There is a fundamental difference between overall survival (OS), simply living longer; and eradicating disease, cure. The scientific underpinning of both our understanding and the recent developments encourages an optimistic view of the remaining hurdles. SUMMARY: There has been an unprecedented explosion in the number of new drugs approved for the treatment of ovarian cancer with three new classes of agent, and five new drugs receiving food and drug administration approval in the last 3 years (Fig. 2). Getting the right drug truly transforms patients' experience with the seminal event being the development of imatinib in CML. In 1980, an average patient would have lived only 3 years, and now they only live 3 years less than a full lifespan [Bower et al. (2016). J Clin Oncol 34:2851].


Asunto(s)
Investigación Biomédica/historia , Medicina Basada en la Evidencia , Neoplasias Ováricas/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/historia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos Antineoplásicos , Investigación Biomédica/métodos , Investigación Biomédica/tendencias , Terapia Combinada/efectos adversos , Terapia Combinada/historia , Aprobación de Drogas/historia , Femenino , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Inmunoterapia Adoptiva/efectos adversos , Inmunoterapia Adoptiva/historia , Terapia Molecular Dirigida/efectos adversos , Terapia Molecular Dirigida/historia , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/historia , Neoplasias Ováricas/mortalidad , Tasa de Supervivencia , Estados Unidos/epidemiología , United States Food and Drug Administration
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA